Article Text

PDF
Maculopathy in patients with primary CNS lymphoma treated with chemotherapy in conjunction with blood–brain barrier disruption
  1. J Vicuna-Kojchen1,
  2. S Frenkel1,
  3. T Siegal2,
  4. E Shalom2,
  5. I Chowers1,
  6. J Pe’er1
  1. 1
    Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
  2. 2
    Gaffin Center for Neuro-Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
  1. Professor Jacob Pe’er, Department of Ophthalmology, Hadassah-Hebrew University Medical Center, POB 12000, Jerusalem 91120, Israel; peer{at}hadassah.org.il

Abstract

Aim: To determine the incidence and characteristics of maculopathy associated with blood–brain barrier disruption (BBBD) which is used in treating primary central nervous system lymphoma (PCNSL).

Methods: Files of all 56 patients with PCNSL, with or without intraocular lymphoma (IOL), treated at Hadassah University Hospital during the years 1997–2007 were reviewed. Data on 46 patients for whom we had documentation of ocular examination were studied. Those who were alive at the time of the data collection were invited for further evaluation of the presence or absence of maculopathy. The patients were divided into four groups according to treatment protocol. Group 1: systemic intravenous chemotherapy; Group 2: systemic intravenous chemotherapy and intravitreal methotrexate (MTX); Group 3: systemic intra-arterial (IA) chemotherapy and BBBD; Group 4: systemic IA chemotherapy, BBBD, and intravitreal MTX.

Results: Of the 23 patients of Groups 1 and 2 who were not treated by BBBD, none developed maculopathy. Of those 23 patients who were treated by BBBD, 12 of 17 (70.5%) in Group 3 and three of six (50%) in Group 4, for a total of 15 of 23 (65.2%) developed maculopathy. The maculopathy did not significantly affect visual acuity in any of them.

Conclusions: BBBD may cause maculopathy in almost two-thirds of patients treated for PCNSL, without affecting significantly the visual acuity. Intravitreal injection of MTX, according to the protocol which we apply, is not associated with maculopathy.

Statistics from Altmetric.com

Footnotes

  • Competing interests: None.

  • Patient consent: Each patient gave their informed consent for the treatment.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.